The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

According to The Business Research Company’s Late Stage Chronic Kidney Disease Drugs Global Market Report 2023, the worldwide late-stage chronic kidney disease drugs market is projected to expand from $5.68 billion in 2022 to $6.38 billion in 2023, with a compound annual growth rate (CAGR) of 12.3%. Anticipated growth indicates that the late-stage chronic kidney disease drugs market is poised to reach $9.84 billion in 2027, with a CAGR of 11.4%.

What was the major driver in the late stage chronic kidney disease drugs market?
The rising incidence of chronic kidney diseases is poised to drive the late-stage chronic kidney disease drug market’s growth. Chronic kidney diseases encompass various conditions that impact kidney structure and function. Late-stage chronic kidney disease drugs are utilized to manage blood pressure, reduce protein loss, halt kidney deterioration, alleviate symptoms, and prevent complications. For example, in July 2022, the Centers for Disease Control and Prevention reported that approximately 15% or 37 million individuals in the US had kidney disease. The prevalence rate was 12% among those aged 45–64 and 6% among those aged 18–44 in 2021. Hence, the prevalence of chronic kidney disease fuels the late-stage chronic kidney disease drug market’s expansion.

View More On The Late Stage Chronic Kidney Disease Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

What was the key trend in the late stage chronic kidney disease drugs market?
Product innovation gains prominence in the late-stage chronic kidney disease drug market, as major companies focus on developing new drugs to maintain market positions. For example, in February 2022, Bayer, a German pharmaceutical and biotechnology company, introduced Kerendia (finerenone) in India. This medication is intended for patients with type 2 diabetes and chronic renal disease and is a non-steroidal, selective mineralocorticoid receptor antagonist, targeting the overactivation of the mineralocorticoid receptor (MR), associated with the development of chronic kidney disease (CKD) and cardiovascular complications.

Which was the largest region in the late stage chronic kidney disease drugs market?
North America was the largest region in the late stage chronic kidney disease drugs market in 2022. The regions covered in late-stage chronic kidney disease drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the late stage chronic kidney disease drugs market prominent players?
Major players in the late stage chronic kidney disease drugs market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc, and Shire plc.

Key late stage chronic kidney disease drugs market segments
The global late stage chronic kidney disease drugs market is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Request A Sample Of The Global Late Stage Chronic Kidney Disease Drugs Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12196&type=smp

The Late Stage Chronic Kidney Disease Drugs Global Market Report 2023  provides a comprehensive overview on the late stage chronic kidney disease drugs market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Kidney Cancer Drugs Global Market Report 2023
Chronic Disease Management Global Market Report 2023
Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model